the short answer
Adequan is an FDA-approved polysulfated glycosaminoglycan injection for signs of canine non-infectious degenerative or traumatic arthritis, given under veterinary direction twice weekly for up to four weeks. BPC-157 is a research peptide, not an FDA-approved veterinary drug, with no controlled canine trials. They are not interchangeable. Adequan has labeled evidence and risks; BPC-157 has an evidence gap. The plan belongs to your vet.
| Adequan (PSGAG) | BPC-157 (our pen) | |
|---|---|---|
| Status | FDA-approved under NADA #141-038 | Research-use; not FDA-approved |
| What it is | Polysulfated glycosaminoglycan (PSGAG) | Synthetic pentadecapeptide |
| Route | Intramuscular injection under vet direction, twice weekly up to 4 weeks (max 8) | Daily subcutaneous click at home |
| Labeled use | Control of signs of non-infectious degenerative or traumatic arthritis | No approved veterinary use |
| Evidence | Label cites a laboratory distribution study and a clinical field trial | Preclinical; no controlled canine trials |
| Labeled adverse events | Transient injection-site pain, diarrhea, abnormal bleeding | Limited safety data; FDA flags immunogenicity and impurities |
| Post-approval reports | Vomiting, anorexia, lethargy, diarrhea; death reported | No comparable post-approval database for this pen |
| Cost | Clinic-billed; weight-based; no national price | $119/28 days; $299/3; $558/6 |
| Best for | Diagnosed arthritis under vet care | Owner wanting a daily research routine with vet agreement |
| Not | Not a cure; not for every dog | Not a pain drug; not an Adequan substitute |
The verdict
These are not alternatives. Adequan is an FDA-approved prescription drug with a labeled indication, a labeled dose, and labeled safety information. BPC-157 is a research peptide with no controlled canine trials and no approved veterinary use. If your dog has arthritis, Adequan may be one option your vet discusses; BPC-157 is not a substitute for it. Do not stop Adequan or any prescribed treatment to try a pen.
What Adequan is
Adequan Canine is polysulfated glycosaminoglycan, 100 mg/mL, for intramuscular use in dogs. The label dose is 2 mg/lb, or 0.02 mL/lb, twice weekly for up to four weeks, with a maximum of eight injections. The labeled indication is the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints. The label says the specific mechanism in canine joints is not known, and it cites a laboratory distribution study and a clinical field trial that showed improvement in range of motion and total orthopedic score versus saline.
What BPC-157 is
BPC-157 is a synthetic peptide studied in preclinical models for tissue repair, gut lining, and blood flow. A 2026 orthopaedic review says human musculoskeletal evidence is limited to one small retrospective uncontrolled case series, and validated dosing, pharmacokinetic, and long-term safety data are lacking. A 2026 systematic review found only three small human studies, judged poor quality with very low certainty. No controlled canine trial has established a dose, a benefit, or long-term safety for the uses owners ask about.
Safety, side by side
Adequan's label lists transient injection-site pain, transient diarrhea, and abnormal bleeding among possible adverse reactions in its clinical trial, and vomiting, anorexia, depression/lethargy, diarrhea, and death in post-approval reports. It is contraindicated in dogs with known or suspected bleeding disorders or hypersensitivity to PSGAG, and it should be used with caution in dogs with renal or hepatic impairment. BPC-157 has far less safety data; the FDA flags immunogenicity and peptide-impurity concerns. Less data is not the same as safer.
Cost and routine
Adequan is often clinic-billed, and the label dose is weight-based, so the number of 5 mL vials depends on your dog's weight. There is no reliable national price, and we will not invent one. BPC-157 in our pen is $119 per 28 days, $299 for three, or $558 for six. The routines are different: Adequan is an intramuscular injection given under veterinary direction twice weekly for up to four weeks; the pen is a daily subcutaneous click at home. Compare the total plan, not the sticker.
What we do not claim
We do not claim BPC-157 is equivalent to Adequan, safer than Adequan, or a replacement for it. We do not claim Adequan is right for every dog or free of risk. We do not claim the pen treats arthritis or changes the need for a vet-prescribed plan. We do not claim a lower sticker price makes two products comparable. The diagnosis and the treatment decision belong to your vet.
Questions owners ask
Is BPC-157 a substitute for Adequan?
No. Adequan is an FDA-approved prescription drug for a labeled arthritis indication; BPC-157 is a research peptide with no controlled canine trials. Do not stop Adequan without your vet.
Which is safer, BPC-157 or Adequan?
They have different data. Adequan has a label, labeled studies, and known adverse events; BPC-157 has much less safety data. Less data does not mean safer.
Can I use BPC-157 and Adequan together?
Ask your vet. There is no controlled canine data on the combination, and Adequan is a prescription product. The decision and timing belong to your vet.
Which is cheaper?
Adequan is often clinic-billed and weight-based, so the total depends on your dog's weight and your clinic's fees. The pen is $119 per 28 days. They are different categories, so compare the total plan, not just the sticker.
Sources
Reviewed October 30, 2026. These are the sources we used for this comparison. Dollar figures are estimates from the named source, not quotes.
- Adequan Canine package insertFDA-approved under NADA #141-038; indication, weight-based dose, labeled and post-approval adverse events.
- Adequan Canine product pageManufacturer indication and safety information for polysulfated glycosaminoglycan.
- FDA: Certain Bulk Drug Substances for Use in CompoundingBPC-157 safety notes; content current April 22, 2026.
- PubMed: Investigational peptides in orthopaedic practice (2026)BPC-157 human musculoskeletal evidence is limited; validated dosing and long-term safety data are lacking.